Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS)

被引:175
|
作者
Kumar, A
Woods, KS
Bartolucci, AA
Azziz, R
机构
[1] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA USA
[3] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA
[4] Univ Alabama, Dept Math & Biostat, Birmingham, AL USA
关键词
D O I
10.1111/j.1365-2265.2005.02256.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the prevalence of adrenal androgen (AA) excess in the polycystic ovary syndrome (PCOS) using age- and race-specific normative values. Design Cross-sectional observational study. Patients One hundred and eight-two (88 Black and 94 White) age-matched healthy eumenorrhoeic nonhirsute women (controls) and 213 (27 Black and 186 White) women with PCOS were recruited. Measurements Total testosterone (T), free T, androstenedione (A4), dehydroepiandrosterone sulfate (DHEAS) and SHBG, as well as fasting insulin and glucose, were measured in plasma. Results The mean total T, free T, A4, DHEAS and body mass index (BMI) were higher in women with PCOS than in control women. DHEAS levels were significantly lower in Black controls than White controls, whereas fasting insulin and BMI were higher in Black controls. In control and Black PCOS women, DHEAS levels did not correlate with BMI, waist-to-hip ratio (WHR) or fasting insulin. Among White women with PCOS, DHEAS levels correlated negatively with BMI and fasting insulin. DHEAS levels decreased similarly with age in control and PCOS women of either race. For each race and age group the upper 95% normative values for log DHEAS was calculated, and the number of PCOS subjects with log DHEAS values above this level were assessed. The prevalence of supranormal DHEAS levels was 33.3% and 19.9%, respectively, among Black and White women with PCOS. Conclusions The prevalence of DHEAS excess is approximately 20% among White and 30% among Black PCOS patients, when using age- and race-adjusted normative values. This study also indicates that the age-associated decline in DHEAS levels is observable and similar in both control and PCOS women, regardless of race. While BMI and fasting insulin had little impact on circulating DHEAS levels in healthy women, among White PCOS patients these parameters were negatively associated with circulating DHEAS levels.
引用
收藏
页码:644 / 649
页数:6
相关论文
共 50 条
  • [21] The association of androgen levels with the severity of hirsutism in the polycystic ovary syndrome (PCOS).
    Huang, A.
    Landay, M.
    Azziz, R.
    [J]. FERTILITY AND STERILITY, 2006, 86 : S12 - S12
  • [22] Polycystic ovary syndrome (PCOS)
    Dewailly, D.
    Hieronimus, S.
    Mirakian, P.
    Hugues, J. -N.
    [J]. ANNALES D ENDOCRINOLOGIE, 2010, 71 (01) : 8 - 13
  • [23] Polycystic Ovary Syndrome (PCOS)
    Milsom, S.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 (04) : E619 - E619
  • [24] Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society
    Wild, Robert A.
    Carmina, Enrico
    Diamanti-Kandarakis, Evanthia
    Dokras, Anuja
    Escobar-Morreale, Hector F.
    Futterweit, Walter
    Lobo, Rogerio
    Norman, Robert J.
    Talbott, Evelyn
    Dumesic, Daniel A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05): : 2038 - 2049
  • [25] Polycystic ovary syndrome (PCOS)
    Jakiel, Grzegorz
    Robak-Cholubek, Dorota
    Tkaczuk-Wlach, Joanna
    [J]. MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2006, 5 (04): : 265 - 269
  • [26] PREVALENCE, INCIDENCE AND TRENDS IN POLYCYSTIC OVARY SYNDROME (PCOS) DIAGNOSIS
    Yu, Onchee
    Christ, Jacob
    Micks, Elizabeth
    Schulze-Rath, Renate
    Hilpert, Jan
    Covey, Jennifer
    Holden, Erika
    Reed, Susan D.
    [J]. FERTILITY AND STERILITY, 2022, 118 (04) : E192 - E192
  • [27] Adrenal Enzyme defects and metabolic Disturbances in Polycystic Ovary syndrome (PCOS).
    Mattle, V
    Kuntner, B.
    Seeber, B.
    Witsch-Baumgartner, M.
    Kraus-Kinsky, E.
    Schulze, E.
    Wildt, L.
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2009, 69 (08) : 768 - 768
  • [28] Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess
    Witchel, SF
    Kahsar-Miller, M
    Aston, CE
    White, C
    Azziz, R
    [J]. FERTILITY AND STERILITY, 2005, 83 (02) : 371 - 375
  • [29] Implications of the 2014 Androgen Excess and Polycystic Ovary Syndrome Society guidelines on polycystic ovarian morphology for polycystic ovary syndrome diagnosis
    Christ, J. P.
    Gunning, M. N.
    Fauser, B. C. J. M.
    [J]. REPRODUCTIVE BIOMEDICINE ONLINE, 2017, 35 (04) : 480 - 483
  • [30] Infertility treatment in patients with polycystic ovary syndrome (PCOS)
    Strowitzki, T
    Hamann, A
    [J]. GYNAKOLOGE, 2002, 35 (01): : 15 - 21